Structure Therapeutics (GPCR) Current Leases (2022 - 2026)
Structure Therapeutics (GPCR) posted quarterly Current Leases of $2.6 million for Q1 2026, up 5.58% year-over-year from $2.5 million in Q1 2025, and down 9.35% quarter-over-quarter from $2.9 million in Q4 2025.
Structure Therapeutics (GPCR) Current Leases (2022 - 2026) Analysis & Trends
Structure Therapeutics' Current Leases history runs 5 years deep, the most recent figure standing at $2.6 million for Q1 2026.
- In Q1 2026, Current Leases rose 5.58% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $2.6 million (up 5.58% YoY), while the FY2025 annual figure was $2.9 million, up 69.49% from the prior year.
- Current Leases for Q1 2026 stood at $2.6 million, down from $2.9 million in the prior quarter.
- The five-year high for Current Leases was $2.9 million in Q4 2025, with the low at $73000.0 in Q2 2023.
- The 5-year median for Current Leases is $1.7 million (2024), against an average of $1.6 million.
- The sharpest annual moves came in 2024 and 2026: Current Leases jumped 2131.51% in 2024, then increased 5.58% in 2026.
- Structure Therapeutics' Current Leases stood at $260000.0 in 2022, then soared by 453.85% to $1.4 million in 2023, then grew by 17.92% to $1.7 million in 2024, then soared by 69.49% to $2.9 million in 2025, then dropped by 9.35% to $2.6 million in 2026.
- Business Quant data shows GPCR's Current Leases at $2.6 million in Q1 2026, $2.9 million in Q4 2025, and $2.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Structure Therapeutics | 11.65 Bn | 11.65 Bn | - | 2.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.60 Mn |
| Mar 31, 2026 | 2.61 Mn |
| Dec 31, 2025 | 2.88 Mn |
| Sep 30, 2025 | 2.80 Mn |
| Jun 30, 2025 | 2.66 Mn |
| Mar 31, 2025 | 2.47 Mn |
| Dec 31, 2024 | 1.70 Mn |
| Sep 30, 2024 | 1.71 Mn |
| Jun 30, 2024 | 1.63 Mn |
| Mar 31, 2024 | 1.60 Mn |
| Dec 31, 2023 | 1.44 Mn |
| Sep 30, 2023 | 817,000.00 |
| Jun 30, 2023 | 73,000.00 |
| Mar 31, 2023 | 168,000.00 |
| Dec 31, 2022 | 260,000.00 |